Skip to content

Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus

Feasibility Study on the Impact of Economic Incentives for Weight Loss to Improve the Management of Type 2 Diabetes Mellitus: REDEEM Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02891382
Acronym
REDEEM-Pilot
Enrollment
54
Registered
2016-09-07
Start date
2016-07-31
Completion date
2017-02-28
Last updated
2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Type 2, Weight Loss, Financial Incentives, Hemoglobin A, Glycosylated

Brief summary

This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify barriers and facilitators linked to the process of implementing each of the interventions. The interventions are based on economic incentives directed to the patient (individual incentives) or a team comprised by the patient and a partner (mixed incentives). Design: Three-month randomized control feasibility study to test the feasibility of implementing three types of intervention with economic incentives in patients with diabetes mellitus. Setting: Diabetes outpatient clinics from a public hospital in Peru.

Detailed description

Economic incentives have been used to promote changes in habits such as smoking and weight loss. However, no studies have been done to determine the impact of this strategy on the management of type 2 diabetes mellitus (T2DM). Additionally, previous studies do not describe ways to determine the amount of an economic incentive to promote behavioral changes, e.g adherence to treatment, increased physical activity and adherence to a healthy diet. There are also questions regarding the frequency of incentives, the type of incentive (cash or other prizes), and the preferred payment method that this study will allow us to explore. Furthermore, we want to test whether a team work approach (mixed incentives) vs. an individual approach (individual incentives) can also play a role in introducing behavioral changes. The goal of the study is to learn about the implementation process of three different interventions that use economic incentives to promote behavioral changes in patients with T2DM, and identify main barriers and facilitators tied to the implementation process of each intervention. This feasibility study will provide key insights to inform a future larger study; specifically, we will * Learn about the experience of participants with T2DM with economic incentives. * Learn about the experience of the companion/team support partners of the participants with T2DM. * Evaluate the patient's receptiveness to and comprehension of the educational materials used to promote behavioral changes. * Evaluate the patient and the companion/team support partner's receptiveness towards the received economic incentive as a tool for promoting behavioral changes. * Explore the companion/team support partner's activities that are most effective in helping with T2DM management of patients. * Explore whether patients with T2DM are able to keep a daily record of their efforts to manage their diabetes. * Evaluate the feasibility of packaging and implementing a future clinical trial that evaluates the impact of the use of economic incentives and teamwork in people with T2DM. From a clinical perspective, we will evaluate the feasibility of reaching the proposed clinical goals in terms of weight loss and HbA1c levels after the intervention period. Interventions Diabetes education (all arms). In the introductory meeting, a diabetes educator will explain to the participants all the procedures, including details of the number of sessions, and the participant's received a manual with information about diabetes management with a tailored weight loss plan. Each participant will be offered up to seven follow- up sessions with the diabetes educator, every two weeks, plus a final session, thus totaling up to 9 one-to-one interactions during the trial, provided that the participant attended all of their meetings. Participants will also be provided with a logbook to register their efforts regarding introducing changes in diet and physical activity. The information from this logbook will provide the starting point for conversations with the diabetes educator during the follow-up sessions, every two weeks. Goal setting (all arms). To determine eligibility for a cash reward, three goals were pre-specified: (1) Weight loss, 80 PEN if the participant loses one kilogram over a period of two weeks, (2) HbA1c level, 200 PEN if the participant achieves, at the end of the study, a decrease in 1% compared to their baseline level, and (3) HbA1c level and control, 400 PEN if the participant achieves, at the end of the study, a decrease ≥1% of A1c or reaches levels of A1c ≤6.5% compared to their baseline level. At the end of the study, targets for weight loss and HbA1c were evaluated independently, i.e. participants could receive more than one reward provided that each independent target was achieved. Companion/team support (Arm 2 and Arm 3). A companion/team support for each participant also receives information about diabetes care in the initial session and a brochure to guide and support the treatment process of the participant. The activities of the companion/team support member will be recorded, and they will be offered to join the follow- up sessions with the patient, every two weeks, but these will not be compulsory. Cash rewards. Two types of rewards will be considered. (1) Individual rewards (Arm 1 and Arm 2), the reward will be provided to the participant. If the participant were to have a companion/team support partner, the cash reward was given to the participant and no rules about sharing the reward (or not) with their companion/team support are established. (2) Shared rewards (Arm 3), i.e. the participant and their companion/team support will receive 50% of the cash reward each.

Interventions

BEHAVIORALDiabetes education

Participants interact with a diabetes educator (DE), every two weeks.

BEHAVIORALGoal setting

Goals for weight loss and change in levels of HbA1c

BEHAVIORALCompanion Support

Patient has a companion/team support partner to support achieving goals.

BEHAVIORALIndividual Reward

The cash reward is given to the patient with diabetes.

BEHAVIORALShared Reward

Patients with diabetes and their companion support will each receive 50% of the cash reward.

Sponsors

Johns Hopkins Bloomberg School of Public Health
CollaboratorOTHER
Universidad Peruana Cayetano Heredia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

for participants: * Type 2 diabetes mellitus * Body mass index 25-39.9 kg/m2, irrespective of HbA1c status * Able to give consent

Exclusion criteria

for participants: * Diagnosis of cancer or another serious comorbidity * Pharmacotherapy for weight loss or corticosteroids * Pregnant women * Blindness, amputation, foot ulcer or being on dialysis * Be companion/team support for another participant in the trial Inclusion criteria for the companion/team support: * Available and committed to supporting the participant in achieving their goals * Able to provide consent

Design outcomes

Primary

MeasureTime frameDescription
Change in Glycated HemoglobinBaseline and 3 monthsHbA1c change at 3 months from baseline

Secondary

MeasureTime frameDescription
Change in WeightBaseline and 3 monthsWeight change at 3 months from baseline

Countries

Peru

Participant flow

Participants by arm

ArmCount
Individual Incentives - Arm 1
This arm receives diabetes education + goal setting + individual rewards Diabetes education: Participants interact with a diabetes educator (DE), every two weeks. Goal setting: Goals for weight loss and change in levels of HbA1c Individual Reward: The cash reward is given to the patient with diabetes.
18
Mixed Incentives (Altruism) - Arm 2 Patients
This arm receives diabetes education + goal setting + companion support + individual rewards Diabetes education: Participants interact with a diabetes educator (DE), every two weeks. Goal setting: Goals for weight loss and change in levels of HbA1c Companion Support: Patient has a companion/team support partner to support achieving goals. Individual Reward: The cash reward is given to the patient with diabetes.
18
Mixed Incentives (Altruism) - Arm 2 Companions
The companion support help the partner to achieve goals. The cash reward is given to the patient with diabetes and not to the companion.
18
Mixed Incentives (Cooperation) - Arm 3 Patient
This arm receives diabetes education + goal setting + companion support + shared rewards Diabetes education: Participants interact with a diabetes educator (DE), every two weeks. Goal setting: Goals for weight loss and change in levels of HbA1c Companion Support: Patient has a companion/team support partner to support achieving goals. Shared Reward: Patients with diabetes and their companion support will each receive 50% of the cash reward.
18
Mixed Incentives (Cooperation) - Arm 3 Companion
The companion support help the partner to achieve goals. Patients with diabetes and their companion support will each receive 50% of the cash reward.
18
Total90

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004
Overall StudyLost to Follow-up34534

Baseline characteristics

CharacteristicIndividual Incentives - Arm 1Mixed Incentives (Altruism) - Arm 2 PatientsMixed Incentives (Altruism) - Arm 2 CompanionsMixed Incentives (Cooperation) - Arm 3 PatientMixed Incentives (Cooperation) - Arm 3 CompanionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants2 Participants3 Participants2 Participants0 Participants9 Participants
Age, Categorical
Between 18 and 65 years
16 Participants16 Participants15 Participants16 Participants18 Participants81 Participants
Age, Continuous54.7 years
STANDARD_DEVIATION 9.8
55.5 years
STANDARD_DEVIATION 9.8
49.8 years
STANDARD_DEVIATION 15.9
54.2 years
STANDARD_DEVIATION 7.6
39.7 years
STANDARD_DEVIATION 16.6
54.4 years
STANDARD_DEVIATION 9
Glycated Hemoglobin8.5 Percentage of glycated hemoglobin
STANDARD_DEVIATION 2.2
7.9 Percentage of glycated hemoglobin
STANDARD_DEVIATION 3.1
8.2 Percentage of glycated hemoglobin
STANDARD_DEVIATION 2.1
8.2 Percentage of glycated hemoglobin
STANDARD_DEVIATION 2.5
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
18 Participants18 Participants18 Participants18 Participants18 Participants90 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Region of Enrollment
Peru
18 Participants18 Participants18 Participants18 Participants18 Participants90 Participants
Sex: Female, Male
Female
12 Participants12 Participants11 Participants12 Participants11 Participants58 Participants
Sex: Female, Male
Male
6 Participants6 Participants7 Participants6 Participants7 Participants32 Participants
Weight76.9 Kg
STANDARD_DEVIATION 10.7
84.5 Kg
STANDARD_DEVIATION 17.4
85.1 Kg
STANDARD_DEVIATION 22.3
82.1 Kg
STANDARD_DEVIATION 17.5

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 180 / 180 / 18
other
Total, other adverse events
0 / 180 / 180 / 18
serious
Total, serious adverse events
0 / 180 / 180 / 18

Outcome results

Primary

Change in Glycated Hemoglobin

HbA1c change at 3 months from baseline

Time frame: Baseline and 3 months

Population: Some participants had data about weight but not about glycated hemoglobin and for that reason the number of participants in this table are different from the table that show the results of weight.

ArmMeasureValue (MEAN)Dispersion
Individual Incentives - Arm 1Change in Glycated Hemoglobin1.4 Percentage of glycated hemoglobinStandard Deviation 1.4
Mixed Incentives (Altruism) - Arm 2Change in Glycated Hemoglobin0.9 Percentage of glycated hemoglobinStandard Deviation 1.2
Mixed Incentives (Cooperation) - Arm 3Change in Glycated Hemoglobin1.1 Percentage of glycated hemoglobinStandard Deviation 1.6
Secondary

Change in Weight

Weight change at 3 months from baseline

Time frame: Baseline and 3 months

Population: Some participants had data about weight but not about glycated hemoglobin and for that reason the number of participants in this table are different from the table that show the results of glycated hemoglobin.

ArmMeasureValue (MEAN)Dispersion
Individual Incentives - Arm 1Change in Weight2.9 KgStandard Deviation 2.2
Mixed Incentives (Altruism) - Arm 2Change in Weight0.4 KgStandard Deviation 2.5
Mixed Incentives (Cooperation) - Arm 3Change in Weight0.4 KgStandard Deviation 3

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026